Expertise in
4
conditions

Graziella Pinotti

ASST Settelaghi
Varese, IT 
Expertise in
4
conditions
ASST Settelaghi
Varese, IT 

Overview

Graziella Pinotti practices practicing medicine in Varese, Italy.

Ms. Pinotti is highly rated in 4 conditions, according to our data. Her clinical expertise encompasses B-Cell Lymphoma, Non-Hodgkin Lymphoma, Breast Cancer, Oophorectomy, and Tissue Biopsy.

She is actively involved in clinical research, co-authoring 58 peer reviewed articles and participating in 5 clinical trials.

Gender

Female

Locations

ASST Settelaghi
Varese, Italy

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

5 Clinical Trials

Phase II Open-label, Multicentre, Randomized Trial of Neoadjuvant Palbociclib in Combination With Hormonal Therapy and HER2 Blockade Versus Paclitaxel in Combination With HER2 Blockade for Postmenopausal Patients With Hormone Receptor Positive/HER2 Positive Early Breast Cancer
Phase II Open-label, Multicentre, Randomized Trial of Neoadjuvant Palbociclib in Combination With Hormonal Therapy and HER2 Blockade Versus Paclitaxel in Combination With HER2 Blockade for Postmenopausal Patients With Hormone Receptor Positive/HER2 Positive Early Breast Cancer
Enrollment Status: Completed
Publish Date: August 26, 2026
Intervention Type: Drug
Study Drugs: Paclitaxel, Trastuzumab, Pertuzumab, Palbociclib, Letrozole
Study Phase: Phase 2
A Study Evaluating the Pregnancy Outcomes and Safety of Interrupting Endocrine Therapy for Young Women With Endocrine Responsive Breast Cancer Who Desire Pregnancy
A Study Evaluating the Pregnancy Outcomes and Safety of Interrupting Endocrine Therapy for Young Women With Endocrine Responsive Breast Cancer Who Desire Pregnancy
Enrollment Status: Active_not_recruiting
Publish Date: February 09, 2026
Intervention Type: Other
Study Phase: Not Applicable
A Randomized Phase II Trial of Metronomic Oral Vinorelbine Plus Cyclophosphamide and Capecitabine (VEX) Versus Weekly Paclitaxel as First-line or Second-line Treatment in Patients With ER-positive/HER2-negative Advanced or Metastatic Breast Cancer
A Randomized Phase II Trial of Metronomic Oral Vinorelbine Plus Cyclophosphamide and Capecitabine (VEX) Versus Weekly Paclitaxel as First-line or Second-line Treatment in Patients With ER-positive/HER2-negative Advanced or Metastatic Breast Cancer
Enrollment Status: Completed
Publish Date: February 26, 2024
Intervention Type: Drug
Study Drugs: Paclitaxel, Cyclophosphamide, Capecitabine, Vinorelbine
Study Phase: Phase 2
A Randomized Phase III Study Of Low-Docetaxel Oxaliplatin, Capecitabine (Low-Tox) Vs Epirubicin, Oxaliplatin And Capecitabine (Eox) In Patients With Locally Advanced Unresectable Or Metastatic Gastric Cancer
A Randomized Phase III Study Of Low-Docetaxel Oxaliplatin, Capecitabine (Low-Tox) Vs Epirubicin, Oxaliplatin And Capecitabine (Eox) In Patients With Locally Advanced Unresectable Or Metastatic Gastric Cancer
Enrollment Status: Terminated
Publish Date: October 09, 2019
Intervention Type: Drug
Study Phase: Phase 3
Maintenance Metronomic Per OS Navelbine In Advanced NSCLC Patients After Previous Platinum Based Chemotherapy: A Multicenter Randomized Best Supportive Care Controlled Phase II Study - MA.NI.LA. Trial
Maintenance Metronomic Per OS Navelbine In Advanced NSCLC Patients After Previous Platinum Based Chemotherapy: A Multicenter Randomized Best Supportive Care Controlled Phase II Study - MA.NI.LA. Trial
Enrollment Status: Completed
Publish Date: April 22, 2019
Intervention Type: Drug
Study Phase: Phase 2
View 4 Less Clinical Trials

58 Total Publications

What patients with cancer think about the dehospitalization. A survey of Cipomo.
What patients with cancer think about the dehospitalization. A survey of Cipomo.
Journal: Recenti progressi in medicina
Published: May 06, 2024

Frequently Asked Questions about Graziella Pinotti

Is Graziella Pinotti a top-rated expert for B-Cell Lymphoma?

MediFind is an objective health platform that identifies experts based on real-world data. Graziella Pinotti is classified as an Advanced expert for B-Cell Lymphoma, meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

Does Graziella Pinotti participate in research or clinical trials?

Yes. Graziella Pinotti has published 58 articles and abstracts on conditions like B-Cell Lymphoma. You can view a list of Graziella Pinotti's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Ms. Pinotti's expertise for a condition
ConditionClose
      View All 25 Experienced Conditions
      Want to save this expert for later?
      Sign Up
      Not sure about your diagnosis?
      Check Your Symptoms
       
       
       
       
      Learn about our expert tiers
      Learn More
      Are you the provider on this profile?
      Claim Profile